---
title: Financial risks and rewards in biotechnology investments
videoId: cwpGBCjpJiU
---

From: [[artedeinvertir]] <br/> 

Bill Gates, one of the world's wealthiest individuals, appears to be preparing for a new crisis similar to past events, as indicated by his significant investments in companies that produce vaccines <a class="yt-timestamp" data-t="00:00:05">[00:00:05]</a>. This represents a "radical change" in his [[investment_opportunities_and_strategies | investment strategy]] <a class="yt-timestamp" data-t="00:00:22">[00:00:22]</a>, with reasons that could be concerning <a class="yt-timestamp" data-t="00:00:25">[00:00:25]</a>. Bill Gates has asserted that it is "practically certain" a new crisis will occur <a class="yt-timestamp" data-t="00:00:14">[00:00:14]</a>.

## Bill Gates' Shifting Investment Focus

Bill Gates has a history of prescience, having warned about the likelihood of a pandemic similar to the one experienced and noting global unpreparedness <a class="yt-timestamp" data-t="00:00:51">[00:00:51]</a>. His deep understanding of the [[analysis_of_bill_gates_favorite_stocks_in_biotechnology | biotechnology sector]] also led him to accurately predict which company would first develop a successful vaccine <a class="yt-timestamp" data-t="00:00:58">[00:00:58]</a>. Beyond his entrepreneurial success with Microsoft, Bill Gates is renowned for his investment acumen, with his movements and statements closely followed by millions of investors globally due to his accurate vision of the future economy and stocks <a class="yt-timestamp" data-t="00:01:19">[00:01:19]</a>.

Recently, his investment portfolio has been made public <a class="yt-timestamp" data-t="00:01:34">[00:01:34]</a>, revealing a preparation for a crisis akin to the one in 2020 <a class="yt-timestamp" data-t="00:01:38">[00:01:38]</a>. He has radically altered his [[stock_market_investments_and_strategies | investment strategy]], concentrating 70% of his investments in just three companies that produce vaccines <a class="yt-timestamp" data-t="00:01:43">[00:01:43]</a>.

### Transparency in US Markets

Due to stock market transparency rules in the United States, institutional investors with over $100 million in assets must periodically report their share purchases and sales to the American regulator <a class="yt-timestamp" data-t="00:02:13">[00:02:13]</a>. This allows insight into Bill Gates' economic and stock market vision through his investments, which are often more revealing than his public statements <a class="yt-timestamp" data-t="00:02:26">[00:02:26]</a>. Bill Gates operates two main investment vehicles: a fund for traditional, safer shares and the portfolio of the Bill & Melinda Gates Foundation, which is the focus of this analysis <a class="yt-timestamp" data-t="00:02:35">[00:02:35]</a>.

## Key Biotechnology Investments

Within the Bill & Melinda Gates Foundation portfolio, three companies—BioNTech, CureVac, and Vir Biotechnology—now constitute over 70% of his total investment <a class="yt-timestamp" data-t="00:02:53">[00:02:53]</a>. These companies are strategically chosen as leaders in the development of "second-generation vaccines," anticipated to be more sophisticated and effective <a class="yt-timestamp" data-t="00:03:03">[00:03:03]</a>.

Investing in [[investment_in_pharmaceutical_sector | biotechnology companies]] in the development phase carries high risk and volatility, requiring a significant level of knowledge for success due to the high rate of failed clinical trials <a class="yt-timestamp" data-t="00:04:01">[00:04:01]</a>. However, successful ventures can yield substantial financial rewards <a class="yt-timestamp" data-t="00:04:14">[00:04:14]</a>.

Examples of past successes include:
*   **BioNTech**: Collaborated with Pfizer to develop an effective vaccine. Even after satisfactory clinical trials were announced, its shares rose from $90 to over $350 <a class="yt-timestamp" data-t="00:04:19">[00:04:19]</a>.
*   **Moderna**: Positioned as a leading vaccine developer, its stock surged from $70 to over $400 in less than 12 months <a class="yt-timestamp" data-t="00:04:37">[00:04:37]</a>.

## Analysis of Specific Stocks

### BioNTech (BNTX)

*   **Ticker**: BNTX <a class="yt-timestamp" data-t="00:05:15">[00:05:15]</a>
*   **Current Price (as of transcript)**: $360 per share <a class="yt-timestamp" data-t="00:05:18">[00:05:18]</a>
*   **Bill Gates' Investment**: Began investing in late 2019, just six months before the crisis <a class="yt-timestamp" data-t="00:05:22">[00:05:22]</a>. An initial $50 million investment grew to over $200 million <a class="yt-timestamp" data-t="00:05:28">[00:05:28]</a>.
*   **Outlook**: BioNTech, alongside Pfizer, was the first to launch an effective vaccine <a class="yt-timestamp" data-t="00:05:33">[00:05:33]</a>. The company projects a recurrent demand of one million doses per year from 2022 onwards <a class="yt-timestamp" data-t="00:05:43">[00:05:43]</a>. For the current year (as of transcript), it was estimated to earn over $37 per share, trading below 10 times earnings, considered a very attractive price for a biotechnology company if the business becomes recurrent <a class="yt-timestamp" data-t="00:06:00">[00:06:00]</a>. Shares could potentially double if valued in line with similar companies, with even greater potential if new clinical trials succeed <a class="yt-timestamp" data-t="00:06:16">[00:06:16]</a>.

### CureVac (CVAC)

*   **Ticker**: CVAC <a class="yt-timestamp" data-t="00:06:32">[00:06:32]</a>
*   **Current Price (as of transcript)**: $70 per share <a class="yt-timestamp" data-t="00:06:34">[00:06:34]</a>
*   **Bill Gates' Investment**: Invested in 2015 with $50 million, now valued at over $230 million <a class="yt-timestamp" data-t="00:06:41">[00:06:41]</a>.
*   **Outlook**: CureVac is a German company collaborating with major firms like GlaxoSmithKline on second-generation vaccines <a class="yt-timestamp" data-t="00:06:52">[00:06:52]</a>. Unlike BioNTech, CureVac is a more speculative and volatile [[analysis_of_specific_investment_opportunities | investment opportunity]] as it is still in the development phase, not yet profitable, and heavily reliant on the success of its clinical trials <a class="yt-timestamp" data-t="00:07:03">[00:07:03]</a>.

### Vir Biotechnology (VIR)

*   **Ticker**: VIR <a class="yt-timestamp" data-t="00:07:40">[00:07:40]</a>
*   **Current Price (as of transcript)**: $48 per share <a class="yt-timestamp" data-t="00:07:41">[00:07:41]</a>
*   **Bill Gates' Investment**: Invested in 2019 <a class="yt-timestamp" data-t="00:07:48">[00:07:48]</a>.
*   **Outlook**: Vir Biotechnology is a highly innovative company developing effective solutions against multiple variants, including the Delta variant, with reported effectiveness levels over 82% <a class="yt-timestamp" data-t="00:07:52">[00:07:52]</a>. An additional factor of interest for Bill Gates may be its development of an inhaled vaccine application method, which could simplify administration and increase public participation <a class="yt-timestamp" data-t="00:08:04">[00:08:04]</a>. Similar to CureVac, Vir Biotechnology is in the development phase, not yet producing benefits, making it a highly speculative and high-risk investment with potential for significant reward <a class="yt-timestamp" data-t="00:08:20">[00:08:20]</a>.

## Bill Gates' Rationale for Biotechnology Investments

Bill Gates has articulated his primary reason for significant [[investment_opportunities_and_strategies | investment opportunities and strategies]] in this sector:
> "We will only return to normal when we have not the first generation of vaccines but the next generation of vaccines. The good news is that there are a large number of companies working to achieve this second generation." <a class="yt-timestamp" data-t="00:08:58">[00:08:58]</a>

His statements and recent portfolio movements provide insight into which companies are best positioned to develop these next-generation vaccines <a class="yt-timestamp" data-t="00:09:09">[00:09:09]</a>. As seen with companies like Moderna or BioNTech, while they develop effective solutions that benefit humanity, they can also generate high returns for their shareholders in the [[stock_market_risks_and_historical_comparisons | stock market]] <a class="yt-timestamp" data-t="00:09:20">[00:09:20]</a>.